• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Gastroenterology

High hepatitis B antigen predicts hepatic cancer recurrence

byAsya OfshteynandChaz Carrier
April 5, 2014
in Gastroenterology, Infectious Disease, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD

1. The risk of hepatocellular carcinoma recurrence increased with high levels of hepatitis B surface antigen (HBsAg), specifically at HBsAg above 1000 IU/mL. 

2. Both 5-year disease-free survival and overall survival was lower in patients with high HBsAg levels, despite low viral loads. 

Evidence Rating Level: 2 (Good)

Study Rundown:  Partial hepatectomy is often an effective treatment option for hepatocellular carcinoma (HCC).  Like in other cancers, it is important to identify risk factors for recurrence of HCC following treatment.  This study looked at Hepatitis B (HBV) positive patients with HCC and found that high preoperative HBsAg levels increased the risk of tumor recurrence after partial hepatectomy, even in absence of high viral loads. This study suggests that HBsAg levels should be used as a prognostic factor for tumor recurrence in this patient population. Although it analyzed a large number of patients, this study is limited by its retrospective nature and its restriction to one academic center. Early tumor occurrence was not associated with high HBsAg levels, and after excluding those with early recurrence, authors were able to show an association with late tumor recurrence. This demonstrates that the 5-year follow-up period was likely too short to capture potentially large differences in disease-free and overall survival rates associated high HBsAg levels.

Click to read the study in JAMA Surgery

Relevant Reading: High Levels of Hepatitis B Surface Antigen Increase Risk of Hepatocellular Carcinoma in Patients With Low HBV Load

RELATED REPORTS

OPTN and UNOS update policy regarding hepatocellular carcinoma [Classics Series]

Radiofrequency thermal ablation superior to percutaneous ethanol injection in hepatocellular carcinoma [Classics Series]

Arterial chemoembolization improves survival in non-resectable hepatocellular carcinoma [Classics Series]

In-Depth [retrospective cohort]: This study performed a retrospective analysis of 1062 patients who previously underwent partial hepatectomy for HBV-related HCC and had a low preoperative HBV viral load. Patients who had antiviral therapy, hepatitis C, anti-HBs antibody positivity, and major early complications or death were excluded. The patients were divided into three groups based on preoperative HBsAg level: less than 100 IU/mL, 100 to 999 IU/mL and 1000 IU/mL or greater. The 5-year disease-free survival (DFS) rates were 48.9%, 43.8% and 34.1% respectively, and the overall survival rates were 59.3%, 56.0% and 48.8% respectively. DFS of patients with HBsAg <999 IU/mL(groups 1 and 2) was significantly greater than in those with the highest preoperative HBsAg level (46.1% vs. 34.1% p=0.002). The difference between the first two groups was not statistically significant. Similarly, the 5-year overall survival rates were higher in the low-HBsAg groups compared to the high-HBsAg group (57.5% vs. 48.8% p=0.004). Preoperative HBsAg level higher than 1000 IU/mL was also associated with a high risk of tumor recurrence in this population (hazard ratio 1.23, 95% CI 1.04-1.44, p=0.1), along with seropositivity for HBeAg, tumor size greater than 5 cm, blood transfusion, surgical margin of less than 1 cm, presence of satellite nodules and portal vein thrombosis. Early tumor recurrence was not associated with high HBsAg, but late tumor recurrence was associated with high HBsAg (in the patients without early tumor recurrence).

More from this author: Feeding tube improves outcomes after rectal resection, Symptomatic relief possible with surgery for metastatic bowel obstruction, Preperitoneal mesh placement a valid option for ventral hernia repair, Surgeons may be unaware of own level of burnout, Home Calculator may predict likelihood of home discharge after surgery

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

 

Tags: hepatitishepatocellular carcinoma
Previous Post

HLA-DRB1*07:01 confirmed as risk factor for lapatinib-induced liver damage

Next Post

Educational sessions as effective as physiotherapy for chronic whiplash pain [PROMISE trial]

RelatedReports

The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Hematology/Oncology Classics

OPTN and UNOS update policy regarding hepatocellular carcinoma [Classics Series]

June 30, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Hematology/Oncology Classics

Radiofrequency thermal ablation superior to percutaneous ethanol injection in hepatocellular carcinoma [Classics Series]

June 30, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Hematology/Oncology Classics

Arterial chemoembolization improves survival in non-resectable hepatocellular carcinoma [Classics Series]

June 29, 2022
Large spike in drug use-associated infective endocarditis linked with opioid epidemic
Gastroenterology

Accessible hepatitis C care for people who inject drugs provide significantly higher rates of cure compared to conventional care

March 17, 2022
Next Post
MRI helps predict risk of local recurrence in upper rectal cancers

Educational sessions as effective as physiotherapy for chronic whiplash pain [PROMISE trial]

Single-site robotic cholecystectomy is safe, but technically challenging

In elderly, robotic surgery for endometrial cancer linked with lower morbidity

Roadway design may decrease risk of child pedestrian collisions

Roadway design may decrease risk of child pedestrian collisions

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Relugolix combination therapy is efficacious for endometriosis-associated pain
  • Age-based products and longer interdose intervals may reduce the risk of cardiac disease following COVID-19 mRNA vaccination
  • OPTN and UNOS update policy regarding hepatocellular carcinoma [Classics Series]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.